Gossamer Bio Operating Expenses Growth & History (GOSS)
Gossamer Bio's operating expenses was $219.2M for fiscal 2025.
View full Gossamer Bio company overviewGossamer Bio annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $219.2M | $44.6M | +25.53% |
| 2024 | 2024-12-31 | $174.6M | −$9.1M | −4.97% |
| 2023 | 2023-12-31 | $183.8M | −$34.8M | −15.94% |
| 2022 | 2022-12-31 | $218.6M | $2.5M | +1.14% |
| 2021 | 2021-12-31 | $216.1M | −$17.8M | −7.62% |
| 2020 | 2020-12-31 | $234.0M | $47.8M | +25.69% |
| 2019 | 2019-12-31 | $186.1M | $37.1M | +24.93% |
| 2018 | 2018-12-31 | $149.0M | $142.3M | +2139.49% |
| 2017 | 2017-12-31 | $6.7M | — | — |
Gossamer Bio quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $35.3M | −$14.9M | −29.73% |
| Q1 2026 | 2026-03-31 | $61.8M | $15.1M | +32.38% |
| Q4 2025 | 2025-12-31 | $59.8M | $14.3M | +31.49% |
| Q3 2025 | 2025-09-30 | $62.4M | $19.0M | +43.80% |
| Q2 2025 | 2025-06-30 | $50.3M | $6.5M | +14.85% |
| Q1 2025 | 2025-03-31 | $46.7M | $4.7M | +11.30% |
| Q4 2024 | 2024-12-31 | $45.5M | −$3.5M | −7.18% |
| Q3 2024 | 2024-09-30 | $43.4M | $2.9M | +7.18% |
| Q2 2024 | 2024-06-30 | $43.8M | −$2.5M | −5.50% |
| Q1 2024 | 2024-03-31 | $42.0M | −$6.0M | −12.48% |
| Q4 2023 | 2023-12-31 | $49.0M | −$5.3M | −9.81% |
| Q3 2023 | 2023-09-30 | $40.5M | −$15.5M | −27.72% |
| Q2 2023 | 2023-06-30 | $46.3M | −$7.6M | −14.06% |
| Q1 2023 | 2023-03-31 | $47.9M | −$6.4M | −11.78% |
| Q4 2022 | 2022-12-31 | $54.4M | $2.7M | +5.22% |
| Q3 2022 | 2022-09-30 | $56.0M | $357,000 | +0.64% |
| Q2 2022 | 2022-06-30 | $53.9M | −$1.7M | −3.10% |
| Q1 2022 | 2022-03-31 | $54.3M | $1.1M | +2.14% |
| Q4 2021 | 2021-12-31 | $51.7M | −$8.4M | −14.02% |
| Q3 2021 | 2021-09-30 | $55.7M | $2.1M | +3.91% |
| Q2 2021 | 2021-06-30 | $55.6M | −$9.7M | −14.91% |
| Q1 2021 | 2021-03-31 | $53.2M | −$1.8M | −3.21% |
| Q4 2020 | 2020-12-31 | $60.1M | $4.3M | +7.71% |
| Q3 2020 | 2020-09-30 | $53.6M | $3.6M | +7.17% |
| Q2 2020 | 2020-06-30 | $65.3M | $19.0M | +40.97% |
| Q1 2020 | 2020-03-31 | $55.0M | $20.9M | +61.59% |
| Q4 2019 | 2019-12-31 | $55.8M | $16.0M | +40.14% |
| Q3 2019 | 2019-09-30 | $50.0M | −$38,000 | −0.08% |
| Q2 2019 | 2019-06-30 | $46.3M | $13.3M | +40.30% |
| Q1 2019 | 2019-03-31 | $34.0M | $7.9M | +30.20% |
| Q4 2018 | 2018-12-31 | $39.8M | — | — |
| Q3 2018 | 2018-09-30 | $50.0M | — | — |
| Q2 2018 | 2018-06-30 | $33.0M | — | — |
| Q1 2018 | 2018-03-31 | $26.1M | — | — |
Gossamer Bio operating expenses trends
Over the last five fiscal years, Gossamer Bio's operating expenses decreased from $234.0M to $219.2M, a change of −$14.8M. The latest reported quarter, Q2 2026, shows $35.3M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gossamer Bio source filings ↗